Eimeria tenella: immunogenicity of arrested sporozoites in chickens

Distinct non-synonymous mutations in cytochrome b highly correlate with decoquinate resistance in apicomplexan parasite Eimeria tenella

BACKGROUND

Protozoan parasites of the genus Eimeria are the causative agents of chicken coccidiosis. Parasite resistance to most anticoccidial drugs is one of the major challenges to controlling this disease. There is an urgent need for a molecular marker to monitor the emergence of resistance against anticoccidial drugs, such as decoquinate.

METHODS

We developed decoquinate-resistant strains by successively exposing the Houghton (H) and Xinjiang (XJ) strains of E. tenella to incremental concentrations of this drug in chickens. Additionally, we isolated a decoquinate-resistant strain from the field. The resistance of these three strains was tested using the criteria of weight gain, relative oocyst production and reduction of lesion scores. Whole-genome sequencing was used to identify the non-synonymous mutations in coding genes that were highly associated with the decoquinate-resistant phenotype in the two laboratory-induced strains. Subsequently, we scrutinized the missense mutation in a field-resistant strain for verification. We also employed the AlphaFold and PyMOL systems to model the alterations in the binding affinity of the mutants toward the drug molecule.

RESULTS

We obtained two decoquinate-resistant (DecR) strains, DecR_H and XJ, originating from the original H and XJ strains, respectively, as well as a decoquinate-resistant E. tenella strain from the field (DecR_SC). These three strains displayed resistance to 120 mg/kg decoquinate administered through feed. Through whole-genome sequencing analysis, we identified the cytochrome b gene (cyt b; ETH2_MIT00100) as the sole mutated gene shared between the DecR_H and XJ strains and also detected this gene in the DecR_SC strain. Distinct non-synonymous mutations, namely Gln131Lys in DecR_H, Phe263Leu in DecR_XJ, and Phe283Leu in DecR_SC were observed in the three resistant strains. Notably, these mutations were located in the extracellular segments of cyt b, in close proximity to the ubiquinol oxidation site Qo. Drug molecular docking studies revealed that cyt b harboring these mutants exhibited varying degrees of reduced binding ability to decoquinate.

CONCLUSIONS

Our findings emphasize the critical role of cyt b mutations in the development of decoquinate resistance in E. tenella. The strong correlation observed between cyt b mutant alleles and resistance indicates their potential as valuable molecular markers for the rapid detection of decoquinate resistance.

Characterization of the Eimeria maxima sporozoite surface protein IMP1

The purpose of this study was to characterize Eimeria maxima immune-mapped protein 1 (IMP1) that is hypothesized to play a role in eliciting protective immunity against E. maxima infection in chickens. RT-PCR analysis of RNA from unsporulated and sporulating E. maxima oocysts revealed highest transcription levels at 6-12h of sporulation with a considerable downregulation thereafter. Alignment of IMP1 coding sequence from Houghton, Weybridge, and APU-1 strains of E. maxima revealed single nucleotide polymorphisms that in some instances led to amino acid changes in the encoded protein sequence. The E. maxima (APU-1) IMP1 cDNA sequence was cloned and expressed in 2 different polyHis Escherichia coli expression vectors. Regardless of expression vector, recombinant E. maxima IMP1 (rEmaxIMP1) was fairly unstable in non-denaturing buffer, which is consistent with stability analysis of the primary amino acid sequence. Antisera specific for rEmaxIMP1 identified a single 72 kDa protein or a 61 kDa protein by non-reducing or reducing SDS-PAGE/immunoblotting. Immunofluorescence staining with anti-rEmaxIMP1, revealed intense surface staining of E. maxima sporozoites, with negligible staining of merozoite stages. Immuno-histochemical staining of E. maxima-infected chicken intestinal tissue revealed staining of E. maxima developmental stages in the lamnia propia and crypts at both 24 and 48 h post-infection, and negligible staining thereafter. The expression of IMP1 during early stages of in vivo development and its location on the sporozoite surface may explain in part the immunoprotective effect of this protein against E. maxima infection.

Role of antibody in immunity and control of chicken coccidiosis

Research has been carried out worldwide to try to elucidate the mechanism of protective immunity against coccidiosis. It was concluded from early studies that cellular immunity is the key to protection against Eimeria, whereas humoral immunity plays a very minor role in resistance against infection. By contrast, other studies have pointed towards the ability of antibody to block parasite invasion, development and transmission and to provide passive and maternal immunity against challenge infection. Herein, recent results demonstrate the ability of antibodies (raised by live immunization or against purified stage-specific Eimeria antigens) to inhibit parasite development in vitro and in vivo and readdress the question of the role of antibody in protection against coccidiosis.

Past and future: vaccination againstEimeria

Eimeriaspp. are the causative agents of coccidiosis, a major disease affecting many intensively-reared livestock, especially poultry. The chicken is host to 7 species ofEimeriathat develop within intestinal epithelial cells and produce varying degrees of morbidity and mortality. Control of coccidiosis by the poultry industry is dominated by prophylactic chemotherapy but drug resistance is a serious problem. Strongly protective but species-specific immunity can be induced in chickens by infection with any of theEimeriaspp. At the Institute of Animal Health in Houghton, UK in the 1980s we showed that all 7Eimeriaspp. could be stably attenuated by serial passage in chickens of the earliest oocysts produced (i.e. the first parasites to complete their endogenous development) and this process resulted in the depletion of asexual development. Despite being highly attenuated, the precocious lines retained their immunizing capacity. Subsequent work led to the commercial introduction of the first live attenuated vaccine, Paracox®, that has now been in use for 20 years. As much work still remains to be done before the development of recombinant vaccines becomes a reality, it is likely that reliance upon live, attenuated vaccines will increase in years to come.

Identification of Eimeria tenella genes encoding for secretory proteins and evaluation of candidates by DNA immunisation studies in chickens

In order to identify secretory proteins as possible new vaccine candidates, a cDNA-library from E. tenella sporozoites was generated in yeast and was used to select secreted and surface proteins. Herein 191 clones were isolated and analysis of the nucleic acid sequences revealed 162 deduced open reading frames with a prediction for signal peptides. These sequences are characterized by high redundancy, comprising 25 unique protein fragments with a high degree of stage specificity. Only three sequences showed identical homology to already known E. tenella proteins. The majority, 16 fragments, revealed homology to known or hypothetical proteins, and six fragments had no sequence homologues in protein databases. In order to obtain optimised conditions for a DNA vaccination trial in chickens, with which our selected new sequences could be tested, we performed variant DNA immunisations with the well-characterized E. tenella antigen SO7. The cDNA of the SO7 antigen was subcloned into two different eucaryotic expression vectors, i.e. pcDNA3 and pVR1012. In addition, the SO7 sequence was fused to the stabilizing sequence of the enhanced green fluorescence protein (EGFP). All SO7 constructs induced a SO7 specific immune response after intramuscular application and no significant differences were found on using constructs with or without the EGFP fusion or with different vector systems. Full-length open reading frames from six selected Eimeria sequences were introduced into the eucaryotic expression vector pcDNA3. Subsequent immunisation trials revealed a decrease in parasite excretion for three constructs after challenge infection in comparison to the control animals. Our approach represents a rapid screening to identify and test putative new vaccine candidates from E. tenella sporozoites that could also be adopted to other apicomplexan parasites.

Challenges in the successful control of the avian coccidia

Eimeria species infect livestock in a host-specific manner and are the cause of the disease, coccidiosis. Control of Eimeria species is essential and is currently dominated by chemotherapy; with vaccination using formulations of live wild-type or attenuated parasites an increasing option. A new generation of subunit, live-vector or DNA vaccination strategies is being sought and determining the identity of suitable antigens remains difficult. Some past and present methods of controlling avian coccidia are discussed briefly and we describe progress with a novel approach to identify immunoprotective antigens as vaccine candidates.

Eimeria tenella: identification of secretory and surface proteins from expressed sequence tags

To identify new vaccine candidates, Eimeria tenella expressed sequence tags (ESTs) from public databases were analysed for secretory molecules with an especially developed automated in silico strategy termed DNAsignalP. A total of 12,187 ESTs were clustered into 2881 contigs followed by a blastx search, which resulted in a significant number of E. tenella contigs with homologies to entries in public databases. Amino acid sequences of appropriate homologous proteins were analysed for the occurrence of an N-terminal signal sequence using the algorithm signalP. The resulting list of 84 entries comprised 51 contigs whose deduced proteins showed homologies to proteins of apicomplexan parasites. Based on function or localisation, we selected candidate proteins classified as (i) secreted proteins of Apicomplexa parasites, (ii) secreted enzymes, and (iii) transport and signalling proteins. To verify our strategy experimentally, we used a functional complementation system in yeast. For five selected candidate proteins we found that these were indeed secreted. Our approach thus represents an efficient method to identify secretory and surface proteins out of EST databases.

The Biology of Avian Eimeria with an Emphasis on their Control by Vaccination

Studies on the biology of the avian species of Eimeria are currently benefiting from the availability of a comprehensive sequence for the nuclear genome of Eimeria tenella. Allied to some recent advances in transgenic technologies and genetic approaches to identify protective antigens, some elements are now being assembled that should be helpful for the development of a new generation of vaccines. In the meantime, control of avian coccidiosis by vaccination represents a major success in the fight against infections caused by parasitic protozoa. Live vaccines that comprise defined populations of oocysts are used routinely and this form of vaccination is based upon the long-established fact that chickens infected with coccidial parasites rapidly develop protective immunity against challenge infections with the same species. Populations of wild-type Eimeria parasites were the basis of the first live vaccines introduced around 50 years ago and the more recent introduction of safer, live-attenuated, vaccines has had a significant impact on coccidiosis control in many areas of the world. In Europe the introduction of vaccination has coincided with declining drug efficacy (on account of drug resistance) and increasing concerns by consumers about the inclusion of in-feed medication and prospects for drug residues in meat. The use of attenuated vaccines throughout the world has also stimulated a greater interest in the vaccines that comprise wild-type parasites and, during the past 3 years worldwide, around 3x10(9) doses of each type of vaccine have been used. The need for only small numbers of live parasites to induce effective protective immunity and the recognition that Eimeria spp. are generally very potent immunogens has stimulated efforts to develop other types of vaccines. None has succeeded except for the licensing, within several countries in 2002, of a vaccine (CoxAbic vaccine; Abic, Israel) that protects via the maternal transfer of immunoglobulin to the young chick. Building on the success of viral vaccines that are delivered via the embryonating egg, an in ovo coccidiosis vaccine (Inovocox, Embrex Inc.) is currently in development. Following successful field trials in 2001, the product will be ready for Food and Drug Administration approval in 2005 and a manufacturing plant will begin production for sale in late 2005. Limited progress has been achieved towards the development of subunit or recombinant vaccines. No products are available and studies to identify potential antigens remain compromised by an absence of effective in vitro assays that correlate with the induction of protective immunity in the host. To date, only a relatively small portfolio of molecules has been evaluated for an ability to induce protection in vivo. Although Eimeria are effective immunogens, it is probable that to date none of the antigens that induce potent protective immune responses during the course of natural infection has been isolated.

The Relationship Between the Anticoccidial Effects of Clindamycin and the Development of Immunity in the Eimeria pragensis/Mouse Model of Large Intestinal Coccidiosis

The therapeutic effect of clindamycin on Eimeria pragensis (E. pragensis) infection in C57BL/6 mice was demonstrated by suppression of oocyst production and the appearance of degenerated endogenous stages of parasite in the intestine. Short-term clindamycin treatment, from 1 to 4 days or 4 to 8 days post infection (pi) at a dose of 800 mg/kg/day was effective to reduce clinical symptoms, oocyst production and schizogonic development. Interestingly, the short-term treatment schedules allowed the development of a measurable degree of protective immunity to challenge infection in the treated mice. In contrast, clindamycin treatment for the full 12 days period, which almost completely inhibited clinical symptoms and oocyst output, prevented the full development of protective immunity in the treated mice. All these data indicate that clindamycin is efficacious as an anti-eimerian agent and that both early and late endogenous developmental stages of E. pragensis exert a deep influence on the development of effective immunity to challenge infection.

AnEimeriavaccine candidate appears to be lactate dehydrogenase; characterization and comparative analysis

AnEimeria acervulinaprotein fraction was identified which conferred partial protection against anE. acervulinachallenge infection. From this fraction a 37 kDa protein was purified and its corresponding cDNA was cloned and shown to encode a lactate dehydrogenase (LDH). Full length cDNAs encoding LDH from two related species,E. tenellaandE. maxima, were also cloned. The homology between the primary amino acid sequences of these threeEimeriaLDH enzymes was rather low (66–80%), demonstrating an evolutionary divergence. ThePlasmodiumLDH crystal structure was used to generate a 3D-model structure ofE. tenellaLDH, which demonstrated that the many variations in the primary amino acid sequences (P. falciparumLDH andE. tenellaLDH show only 47% identity) had not resulted in altered 3D-structures. Only a single LDH gene was identified inEimeria, which was active as a homotetramer. The protein was present at similar levels throughout different parasitic stages (oocysts, sporozoites, schizonts and merozoites), but its corresponding RNA was only observed in the schizont stage, suggesting that its synthesis is restricted to the intracellular stage.

A single dose of recombinant Salmonella typhimurium induces specific humoral immune responses against heterologous Eimeria tenella antigens in chicken

Salmonella typhimurium vaccine strains were used as antigen delivery system for oral immunisation of chickens against two antigens of the coccidian parasite Eimeria tenella. The cDNAs of the known E. tenella proteins, SO7 and TA4, were isolated from total RNA and subcloned into the expression vectors pQE30 and pTECH2. Subcutaneous immunisation of chickens with Escherichia coli-expressed SO7 and TA4 revealed that both proteins were immunogenic. Both cDNAs were subcloned into plasmids of the pTECH2 vector system, which allows them to be expressed as fusion proteins with the highly immunogenic fragment C of the tetanus toxin under control of the anaerobically inducible nirB promoter. Plasmids were introduced into the S. typhimurium vaccine strains SL3261, C5aroD and C5htrA. SDS-PAGE and Western blot analysis revealed expression of both fusion proteins in all strains under anaerobic culture conditions. Three-week-old white leghorn chickens were orally immunised with 10(9) CFU per animal. The stability of the recombinant bacteria was revealed by recovery of viable Salmonella containing the respective plasmids from the liver of the immunised chickens at day 3 after inoculation. Specific serum IgG antibodies against the SO7-or TA4-antigens were detectable by ELISA 2 weeks after oral immunisation and remained for at least 6 weeks, while specific IgA antibodies were restricted to the bile of the birds. All chickens produced serum IgG and IgA to S. typhimurium lipopolysaccharides. Our data show that a single oral inoculation with recombinant S. typhimurium SL3261, C5aroD and C5htrA can induce specific antibody responses to heterologous Eimeria antigens in chickens, suggesting that recombinant Salmonella are a suitable delivery system for vaccines against Eimeria infections.

Anticoccidial vaccines for broiler chickens: pathways to success

The use of live vaccines, either attenuated or non-attenuated, for the control of coccidiosis due to Eimeria infections in broiler breeder or layer chickens is well established. Use in broilers, however, has been slow to gain acceptance. This has been partly for economic reasons, but also because of perceived adverse effects on early chick growth, particularly with non-attenuated vaccines, and concerns about timely onset of protective immunity in such short-lived birds. This review describes advances in understanding of epidemiological factors and recent improvements of administration methods that have helped to allay these fears and to make the use of anticoccidial vaccines in broilers technically achievable. Topics discussed include: (1) types of commercially available vaccine, (2) vaccines in development, (3) vaccination methods and equipment, (4) basis of vaccine efficacy and immunogenic variation of parasites, (5) key factors in the survival, sporulation and dissemination of vaccinal oocysts, (6) descriptions and significance of patterns of litter oocyst accumulation and occurrence of intestinal lesions in vaccinated flocks, (7) rotation of anticoccidial vaccination and chemotherapy to restore drug sensitivity to resistant wild-type coccidia, (8) combinations of anticoccidial vaccination and chemotherapy, (9) interactions between coccidiosis and clostridiosis in broilers and compatibilities of potential control methods, (10) published performance data for live anticoccidial vaccines in broilers, (11) possible further developments of live vaccines.

Advances and prospects for subunit vaccines against protozoa of veterinary importance

Protozoa are responsible for considerable morbidity and mortality in domestic and companion animals. Preventing infection may involve deliberate exposure to virulent or attenuated parasites so that immunity to natural infection is established early in life. This is the basis for vaccines against theilerosis and avian coccidiosis. Vaccination may not be effective or practical with diseases, such as cryptosporidiosis, that primarily afflict the immune-compromised or individuals with an incompletely developed immune system. Strategies for combating these diseases often rely on passive immunotherapy using serum or colostrums containing antibodies to parasite surface proteins. Subunit vaccines offer an attractive alternative to virulent or attenuated parasites for several reasons. These include the use of bacteria or lower eukaryotes to produce recombinant proteins in batch culture, the relative stability of recombinant proteins compared to live parasites, and the flexibility to incorporate only those antigens that elicit "protective" immune responses. Although subunit vaccines offer many theoretical advantages, our lack of understanding of immune mechanisms to primary and secondary infection and the capacity of many protozoa to evade host immunity remain obstacles to developing effective vaccines. This review examines the progress made on developing recombinant proteins of Eimeria, Giardia, Cryptosporidium, Toxoplasma, Neospora, Trypanosoma, Babesia, and Theileria and attempts to use these antigens for vaccinating animals against the associated diseases.

Progress on developing a recombinant coccidiosis vaccine

The past 10 years of research aimed at developing subunit vaccines against a number of apicomplexans, including Eimeria, Plasmodium and Toxoplasma, have, if anything, revealed the complex nature of parasite-host interactions. The Knowledge gained from this research has shown why developing a subunit vaccine based on a single recombinant antigen from one developmental stage of the parasite was an overly optimistic approach. Many apicomplexan parasites have acquired unique strategies to evade host immunity. The variable expression of genes encoding erythrocyte membrane protein 1 of Plasmodium falciparum [1] (Berendt et al. Parasitology 1994;108:S19-S28) exemplifies one such strategy. The particular mechanism for evading immune destruction depends on a number of interrelated factors, not least of which is the parasite life-cycle and the availability of susceptible hosts. The goal of any vaccine, be it an attenuated organism or a recombinant antigen, is to break the cycle of infection. The development of a recombinant vaccine against apicomplexan parasites will depend on identifying those antigens and intracellular processes that are vital to the parasite survival and those which exist merely as a way of evading immunity. The information that follows is a review of both molecular biology/biochemistry of eimerian parasites and factors that influence host immune responses to coccidia.

Analysis of immunological cross-protection and sensitivities to anticoccidial drugs among five geographical and temporal strains of Eimeria maxima

Two laboratory strains (USDA strain No. 68 isolated from the eastern shore of Maryland 15 years ago and a University of Guelph strain isolated from an Ontario broiler house 23 years ago) and 3 recent field strains of Eimeria maxima [isolated in Maryland (MD), North Carolina (NC) and Florida (FL)] were tested for their ability to induce cross-protective immunity and their sensitivities to a variety of anticoccidial compounds. To assess immunological cross-protection, 1-day-old chicks were inoculated and subsequently challenged at 10 days of age, testing all possible combinations of initial inoculating (immunizing) and subsequent challenge strain. Six days post-challenge, chicks were killed and weight gains and lesion scores were determined and compared to sham inoculated and challenged, and sham challenged age-matched controls. The 2 laboratory strains and the NC strain were fully cross-protective against each other by both these measures. In contrast, the MD and FL strains induced complete protection only against the homologous strain. Reciprocally, no other strains protected chicks completely against the FL and MD strains. Drug sensitivity studies using 10 different anticoccidial formulations at prescribed drug levels showed significant differences between the 2 laboratory strains and the 3 recently isolated field strains; more recent isolates from commercial broiler houses demonstrated complete or partial resistance to a wider range of anticoccidial compounds. No correlation was seen between cross-protection and sensitivities to anticoccidials.

Efficacy of decoquinate against Neospora caninum tachyzoites in cell cultures

Neospora caninum is a major cause of abortion in dairy cattle in the United States and other countries. Abortions and neonatal mortality also occur in other ruminant species. Decoquinate is an anticoccidial that is approved for use in cattle and goats in the United States. We studied the efficacy of decoquinate against tachyzoites of N. caninum in a 5-day of treatment, cell culture flask lesion-based assay. Decoquinate killed tachyzoites at concentrations of 0.1 and 0.01 microgram ml-1. Decoquinate had little measurable effect on extracellular tachyzoites. Decoquinate acted quickly to kill intracellular stages at coccidiocidal concentrations; tachyzoites were killed within 5 min at 0.1 microgram ml-1 decoquinate.

Research on avian coccidia: an update

Despite the availability of many anticoccidial drugs, infections caused by species of Eimeria continue to be a source of significant economic loss to the poultry industry. After two decades in which the use world wide of ionophorous antibiotics gave unparalleled control of coccidiosis, drug resistance is once again tipping the balance in favour of the parasites. The realization that even the most spectacularly successful drugs might, after all, have a finite life if not used conservatively, has focused attention on ways in which the life span of drugs can be prolonged. Many drugs with different (if unknown) modes of action are available, and a variety of shuttle and rotation programmes can be considered. In view of the limitations of chemotherapy, particularly for the rearing of replacement flocks, there is considerable interest in the development of vaccines. Prospects for the introduction of live vaccines based on attenuated parasites are now very good, but the availability in the future of genetically engineered vaccines is more uncertain as little is known about the parasite molecules that stimulate protective immunity and, even if isolated, how they can be administered to the host so that it responds in the immunologically correct manner. Current research on Eimeria spp. in the chicken is broadly representative of that being done on other coccidia. Many lines of investigation are not connected with the development of new drugs or vaccination per se (and therefore have no obvious practical applications), but they are providing new insights into the biological complexity of the organisms and the ways in which they interact with their hosts. It remains possible, however, that a more detailed understanding and analysis of the molecules that are essential in the maintenance of the parasitic life style can be exploited in the future to provide alternative targets for chemical or immunological attack. The research topics considered in this review are arbitrarily grouped as studies on: (1) the basic biology of parasites, including aspects of the life cycle, and structure and function of the apical organelles; (2) the molecular biology of the parasites, including analyses of the number and structure of chromosomes, characterization of DNA sequences, and an account of the viral RNA that has been found in some species of Eimeria; and (3) control of coccidiosis, encompassing first immunity and the development of vaccines, and secondly, chemotherapy.

X-irradiation of Eimeria tenella oocysts provides direct evidence that sporozoite invasion and early schizont development induce a protective immune response(s)

Sporulated oocysts of the protozoan parasite Eimeria tenella were attenuated by exposure to various doses of X-radiation to inhibit intracellular replication and thus determine whether sporozoites alone can induce a protective immune response. Exposure to doses greater than 15-kilorads had a significant effect on development, as indicated by the absence of oocyst production in chickens infected with parasites treated with 20 or 30 kilorads of radiation. Infection with nonirradiated or 15-kilorad-exposed parasites led to either normal or reduced oocyst shedding. Equivalent protection was afforded chickens inoculated with a minimum immunizing dose of either nonirradiated or 20-kilorad-irradiated E. tenella oocysts. Immunofluorescence staining of cecal tissue from chickens inoculated with 10(7) nonirradiated or 20- or 30-kilorad-irradiated oocysts with stage-specific monoclonal antibodies showed no significant difference in sporozoite invasion between treatment groups. Normal merogonic development was observed at appropriate times (48, 60, 72, and 96 h) postinfection in chickens inoculated with nonirradiated oocysts. In contrast, irradiated parasites exhibited minimal merogonic development at 48 h postinfection. Furthermore, no merogonic stages were observed at times of otherwise peak merozoite development (60, 72, and 96 h) in cecal tissue from chickens inoculated with irradiated parasites. Infection of chicken cells with irradiated or nonirradiated parasites in vitro corroborated these findings and indicate that events early after sporozoite invasion induce a protective immune response against this parasite.

Development of resistance to coccidiosis in the absence of merogonic development using X-irradiated Eimeria acervulina oocysts

Sporulated oocysts of the protozoan Eimeria acervulina were subjected to 0, 10, 15, 20, or 30 krad of X-irradiation and inoculated into susceptible outbred chickens to determine if radioattenuated coccidia could induce protection against parasite challenge. Irradiation treatment had an appreciable dose-dependent effect on parasite development. Insignificant numbers of oocysts were produced by chickens inoculated with parasites that had been exposed to greater than 10 krad X-irradiation. Sporozoites exposed to 15 or 20 krad irradiation conferred significant protection against the appearance of intestinal lesions after parasite challenge. Sporozoites subjected to the highest dose level (30 krad) did not produce any significant level of protection. To investigate this phenomenon further and assess intracellular parasite development, susceptible outbred strains of chickens were administered either nonirradiated (0 krad) oocysts or oocysts that were exposed to an optimal dose (15 krad) or a high dose (30 krad) of X-irradiation. Immunofluorescence staining of tissue sections from each treatment group at various intervals after the initial administration of irradiated parasites indicated that sporozoites exposed to 15 krad irradiation were as capable of invading the host intestinal epithelium as nonirradiated sporozoites. However, at 48, 60, 72, and 96 hr, there was a marked reduction in merogonic development in groups receiving irradiated sporozoites compared to those inoculated with nonirradiated parasites. The latter parasites underwent profuse merogonic development; in contrast, irradiated parasites demonstrated little (15 krad) or no (30 krad) merogonic development. These results suggest that induction of a protective immune response occurs during a critical period early in intracellular development of E. acervulina.

Interferon-gamma-mediated effects upon immunity to coccidial infections in the mouse

The effect of treatment with a monoclonal antibody (MoAb) capable of neutralising interferon-gamma (IFN-gamma) on the course of coccidial infections in mice (C57BL/6 and NIH infected with Eimeria vermiformis or E. pragensis, and BALB/c infected with E. pragensis) was examined. The results differed with the species of parasite, the strain of mouse, the measure of infection and whether the infection was a primary or secondary one. The replication of E. vermiformis in primary infections was enhanced in both C57BL/6 and NIH mice, but less MoAb was required in NIH than in C57BL/6 to produce similar effects. In neither strain did treatment prevent priming or interfere with the complete immunity to challenge normally induced by moderate infection with E. vermiformis. The replication of E. pragensis in primary infections was not affected in any of the strains of mouse but the clinical effects were exacerbated. Priming with E. pragensis was unaffected by treatment but the partial immunity to challenge, normally induced by infection with this species, was reduced when MoAb was given 2 h before challenge. This reduction was evident as an increased faecal output of oocysts and loss of body weight. These results confirm the role of IFN-gamma in resistance to coccidiosis and further emphasise the complexity of the immune response in this disease.

Eimeria acervulina: cloning of a cDNA encoding an immunogenic region of several related merozoite surface and rhoptry proteins

A cDNA encoding a recombinant Eimeria acervulina antigen, designated EAMZp30-47, that contains an epitope shared among several surface and rhoptry proteins of merozoites was characterized. The respective parasite proteins are between 30 and 47 kDa as revealed by immunostaining of nitrocellulose membrane containing extracts of 125I-labeled merozoites. As indicated by immunofluorescence and immunoelectron microscopic staining, the reactive epitope was localized to both the surface membrane and the internal rhoptries of this asexual stage of the parasite. The recombinant beta-galactosidase fusion protein EAMZp30-47 is 130 kDa, thus representing 15 kDa or 30-50% of the respective parasite protein. Purified EAMZp30-47 stimulates T cells from E. acervulina-immune inbred chickens, but is not recognized by immune chicken serum, suggesting that T cell and not B cell epitopes recognized by the host immune system during a natural infection are present on the recombinant protein. Northern and Southern blot hybridization experiments indicated that expression of EAMZp30-47 is restricted to the merozoite stage of the parasite and the gene occurs as a single copy sequence within the genome.

Genetically engineered antigen confers partial protection against avian coccidial parasites

A fusion protein of beta-galactosidase and Eimeria tenella produced in a recombinant Escherichia coli strain was injected into chickens and elicited partial protection against an oral challenge with Eim. tenella parasites. The fusion protein contained a 31 kilodalton (kD) coccidial antigen designated as 5401. The DNA sequencing of the 5401 antigen-coding sequence revealed that this protein segment was highly negatively charged and strongly hydrophilic, and contained an amino-acid sequence repeated five times. A dose-titration study showed that immunizing chickens with a single subcutaneous injection of the 5401 antigen at 1,200 to 4,800 nanograms (ng)/bird in Freund's complete adjuvant decreased lesion scores, mortality, and feed conversions compared to unimmunized, challenged controls. Using the 1,200 and 2,400 ng/bird of the 5401 antigen, group weight gains were higher than for the unimmunized, challenged birds. In three other trials using the 5401 antigen at 2,400 ng/bird with light, medium, and heavy coccidial infections, significant protection was evidenced by reduced lesion scores, increased individual weight gains, or both. In addition, feed conversions were reduced when compared with unimmunized controls or birds immunized with a noncoccidial protein E. coli extract. Western blot analysis of sporozoite preparations with serum from 5401-immunized birds labeled two antigenic bands of 66 and less than 200 kD. These results indicate that the coccidial proteins produced in E. coli are potentially effective immunogens for protecting chickens against avian coccidiosis.

cDNA encoding an immunogenic region of a 22 kilodalton surface protein of Eimeria acervulina sporozoites

cDNA encoding an immunogenic region of a 22 kDa surface protein of Eimeria acervulina sporozoites was cloned and expressed in the bacteriophage lambda gt11 vector. The recombinant beta-galactosidase fusion protein, designated MA1, has an apparent molecular size of 125 kDa. Immunofluorescence staining of intact E. acervulina sporozoites and merozoites and immunoblotting of 125I-surface labeled protein from both stages revealed exclusive expression of the cloned cDNA in the sporozoite stage. The gene encoding the 22 kDa surface protein appears to exist as a single copy sequence as revealed by Southern blot hybridization utilizing the cDNA insert as a probe. Although not recognized by immune serum, purified recombinant MA1 antigen induced significant in vitro activation of T lymphocytes obtained from chickens immune to E. acervulina. DNA sequencing and hydropathic analysis of the predicted amino acid sequence revealed a central hydrophilic region surrounded by two hydrophobic areas which may represent exposed and transmembrane regions of the protein.

Eimeria tenella: immunological diversity between asexual generations

In the development of a normal strain, WIS, of Eimeria tenella there are three generations of schizogony whereas in an attenuated line, WIS-F-96, derived from WIS, the second and third are absent. Chickens immunized by infection with WIS-F-96, however, were highly resistant to oral challenge with sporulated oocysts of WIS, and histological studies indicated that the immune response was directed against the sporozoites from that challenge inoculum. When challenge of the WIS-F-96-primed chickens consisted of second generation merozoites of WIS (inoculated intracaecally), immunity was less pronounced and the histological data indicated that the merozoites proceeded to develop normally in these birds. These indications of immunological diversity between the merozoites of the first and second generations of schizogony of E. tenella WIS correlated with the results of preliminary studies of the antigenic composition of these developmental stages.

Identification of immunodominant surface antigens of Eimeria acervulina sporozoites and merozoites

Immunodominant surface antigens of Eimeria acervulina sporozoites and merozoites were identified by 125I-labeling and immunoblotting studies. Using these methodologies 60% of the immunodominant sporozoite antigens and 90% of the immunodominant merozoite antigens were observed to be 125I-surface labeled. However, several major 125I-labeled sporozoite and merozoite proteins did not represent prominent antigens as measured by immunoblotting. Immunodominant surface antigens were found over a wide size range for sporozoites (21-110 kDa) and for merozoites (20-250 kDa). In order to relate these findings to a 'natural' infection, two groups of 3-week old chickens were inoculated 5 times over a 2.5 week period with either a low or high dose of E. acervulina oocysts. The serum response to sporozoites and merozoites, indicated by enzyme-linked immunosorbent assay titers, was rapid; less than or equal to 7 days post-infection with 10(4) oocysts and less than or equal to 3 days with 10(5) oocysts. Many of the antigens identified by immunoblotting of sera from sporozoite- and merozoite-immunized animals were recognized by sera from both high dose and low dose E. acervulina-infected chickens. Furthermore, the sporozoite and merozoite antigens could be grouped into those constituents which induced a serum response early or late in the infection.

The extraintestinal stages of Eimeria tenella and E. maxima in the chicken

Donor chickens given feed medicated with one or two levels of decoquinate or given non-medicated feed were infected with oocysts of Eimeria tenella or E. maxima per os. Twelve hours after inoculation with oocysts liver, mid-intestine or ceca homogenates were fed to previously uninfected recipient chickens. The results showed that continuous medication with decoquinate was effective in preventing the transfer of sporozoites from the intestine to the liver. Oocysts were detected in the feces of all recipients of tissue from non-medicated donors, showing that some sporozoites of E. maxima and E. tenella are normally transferred to liver. Young broiler chickens were immunized by oral inoculation of E. maxima oocysts. The immune status of similar chickens inoculated with sporozoites of the same species directly into the liver or spleen were assessed. During the experimental period half of the chicks were provided with non-medicated food and the remainder were given feed supplemented with decoquinate; decoquinate was effective in arresting the development of the sporozoites. Two weeks after initial infection the birds were challenged with oocysts of E. maxima per os. Injection of sporozoites into the spleen did not protect against challenge. Birds inoculated with sporozoites into the liver were unable to develop a significant level of immunity. When the drug pressure was removed from these birds, parasitism of the intestine occurred and immunity developed.